IL-6 acts as a growth factor together with IL-10 in NHL [101,102] and has been demonstrated to be involved in the resistance of PI3K pathway-targeted treatments via STAT3 or STAT5 activation [103]. This evidence concerns the gene IL10 and non-Hodgkin lymphoma.